Drug Use-Results Survey of Betanis Tablets 25 and 50 mg

This survey aims to determine the following information and the need for conducting specified drug use-results surveys and post-marketing clinical studies in patients using Betanis (generic name: mirabegron):

1. The occurrence of adverse drug reactions in clinical settings.
2. Factors potentially impacting safety, effectiveness, and other aspects.

Items of Particular Interest:

• Safety and effectiveness in patients with hepatic impairment and patients with renal impairment.
• Safety and effectiveness when mirabegron is used concomitantly with other drugs (α1 blockers, anticholinergic agents, 5α reductase inhibitors, drugs with a potent CYP3A4-inhibiting effect, drugs with a CYP3A4-inducing effect, drugs metabolized primarily by CYP2D6, and other frequently used drugs).
• The occurrence of cardiovascular adverse events.
• The occurrence of adverse events related to increased intraocular pressure.
• The occurrence of urinary retention